{"success":true,"data":{"pressRelease":{"id":"167707","rtpr_id":"nPn5w6VZwa-20261013","ticker":"UCB","exchange":"","all_tickers":["UCB"],"title":"UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis","author":"PR Newswire","published_at":"2026-10-13T13:00:27.621Z","article_body":"UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis\nPR Newswire\n\nATLANTA, Oct. 13, 2026\n\n * The Wear It Out program was created with and for patient advocates to reduce\nstigma and increase awareness of the everyday, often unseen compromises and\ndecisions people make because of their conditions.\n * Artist Sophia Yeshi brought real stories of people living with HS, PSO, and\nPsA to life in the form of a t-shirt, transforming them into a wearable\nexpression of connection and self-expression.\n * If you're living with HS, PSO, or PsA, visit\nGoWearItOut.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=3366111021&u=https%3A%2F%2Fwww.gowearitout.com%2F&a=GoWearItOut.com)\n\n to learn how to submit your story, join the community, and receive your\none-of-a-kind Wear It Out t-shirt.\nATLANTA, Oct. 13, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical\ncompany, today announced the launch of Wear It Out\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=2190091215&u=https%3A%2F%2Fwww.gowearitout.com%2F&a=Wear+It+Out)\n, a program created with and for people living with hidradenitis suppurativa\n(HS), plaque psoriasis (PSO), and psoriatic arthritis (PsA). Together, these\nconditions affect millions of people in the U.S., with approximately 2.5\nmillion people living with HS, and approximately 11.3 million people living\nwith PSO or PsA. Developed alongside patient advocates and acclaimed artist\nSophia Yeshi, the Wear It Out program showcases the everyday, often unseen\ndecisions and compromises people make because of their conditions.\n\nWear It Out was born from listening to the community and recognizing a shared\ndesire to feel seen, understood, and empowered. For many people living with\nHS, PSO, and PsA, the impact of disease extends beyond physical symptoms,\nshaping the choices other people often take for granted, like what to wear.\nFor some living with HS, white clothing may feel off limits because drainage\nor leakage from a flare could show. For those living with PSO, black clothing\ncan make flaking more visible, while PsA symptoms, such as stiff or painful\njoints, can make getting dressed, including fastening buttons, more difficult.\n\n\"Getting dressed should not be a strategic decision, and feeling comfortable\nin your own body should never feel out of reach, but for many people with HS,\nPSO, or PsA, it can be–quietly ruling out a white or black shirt or skipping\nan invitation because of what the condition may show,\" said Brittany Blair,\nHead of Patient Strategy, U.S. Immunology, UCB. \"Wear It Out transforms that\nquiet calculation into a visual community symbol worth celebrating and it is a\nreminder that no one should have to settle for less than feeling like\nthemselves in their healthcare journey.\"\n\nAt the center of Wear It Out is a collection of one-of-a-kind,\ncondition-conscious t-shirts, which reclaim those familiar colors as symbols\nof the choices others may never understand. Inspired by the real stories of\npeople living with HS, PSO, and PsA, and brought to life by Brooklyn-based\ngraphic designer and illustrator Sophia Yeshi, each t-shirt design transforms\nlived experiences into a wearable expression of connection and\nself-expression. White and black tees are no longer just everyday wardrobe\nstaples, but reminders that the experiences behind them deserve to be\nrecognized.\n\n\"My work explores themes of identity, resilience, and belonging, so when I was\ngiven the opportunity to create something beautiful out of the often\nchallenging experiences of real people living with these conditions, I was so\ninspired,\" said Sophia Yeshi, graphic designer and illustrator at Yeshi\nDesigns. Every person who shared their story brought a unique perspective and\nsense of strength to this project. My goal was to create artwork that honors\nthose experiences and reflects the beauty, courage, and individuality of the\ncommunity, and thanks to the patients and advocates involved, I think we\nachieved that.\"\n\nThrough shared experiences, community storytelling, and opportunities for\nconnection, the program encourages individuals to celebrate the moments that\nmatter most, whether that means wearing a color they once avoided,\nreconnecting with loved ones, saying yes to new opportunities, or simply\nshowing up with greater confidence.\n\nHS, PSO, and PsA community members can visit GoWearItOut.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=3366111021&u=https%3A%2F%2Fwww.gowearitout.com%2F&a=GoWearItOut.com)\n to join the Wear It Out community, receive resources, and share their own\nstory via video or audio to receive a condition-conscious t-shirt.\n\nFor further information, contact UCB:\n\nInvestor Relations\nYvonne Naughton\nT: +44.175.344.7521\nEmail: Yvonne.Naughton@ucb.com (mailto:Yvonne.Naughton@ucb.com)\n\nSahar Yazdian\nT: +32.2.559.91.37\nEmail: Sahar.Yazdian@ucb.com (mailto:sahar.yazdian@ucb.com)\n\nCorporate Communications\nLaurent Schots\nT: +32.2.559.92.6\nEmail: Laurent.Schots@ucb.com (mailto:Laurent.schots@ucb.com)\n\nU.S. Communications\nNicole Herga\nT +1.773.960.5349\nEmail: Nicole.Herga@ucb.com (mailto:Nicole.Herga@ucb.com)\n\nAbout UCB\nUCB, Brussels, Belgium (www.ucb.com)\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=1188503714&u=http%3A%2F%2Fwww.ucb.com%2F&a=(www.ucb.com))\nis a global biopharmaceutical company focused on the discovery and development\nof innovative medicines and solutions to transform the lives of people living\nwith severe diseases of the immune system or of the central nervous system.\nWith approximately 9,000 people in approximately 40 countries, the company\ngenerated revenue of $ 7.7 billion in 2025. UCB is listed on Euronext Brussels\n(symbol: UCB)\n\nForward-looking statements\nThis document contains forward-looking statements, including, without\nlimitation, statements containing the words \"potential\", \"believes\",\n\"anticipates\", \"expects\", \"intends\", \"plans\", \"seeks\", \"estimates\", \"may\",\n\"will\", \"continue\" and similar expressions. These forward-looking statements\nare based on current plans, estimates and beliefs of management. All\nstatements, other than statements of historical facts, are statements that\ncould be deemed forward-looking statements, including estimates of revenues,\noperating margins, capital expenditures, cash, other financial information,\nexpected legal, arbitration, political, regulatory or clinical results or\npractices and other such estimates and results. By their nature, such\nforward-looking statements are not guaranteeing future performance and are\nsubject to known and unknown risks, uncertainties, and assumptions which might\ncause the actual results, financial condition, performance or achievements\nof UCB, or industry results, to be materially different from any future\nresults, performance, or achievements expressed or implied by such\nforward-looking statements contained in this document.\n\nImportant factors that could result in such differences include but are not\nlimited to: global spread and impacts of wars, pandemics and terrorism, the\ngeneral geopolitical environment, climate change, changes in general economic,\nbusiness and competitive conditions, the inability to obtain necessary\nregulatory approvals or to obtain them on acceptable terms or within expected\ntiming, costs associated with research and development, changes in the\nprospects for products in the pipeline or under development by UCB, effects of\nfuture judicial decisions or governmental investigations, safety, quality,\ndata integrity or manufacturing issues, supply chain disruption and business\ncontinuity risks; potential or actual data security and data privacy breaches,\nor disruptions of UCB's information technology systems, product liability\nclaims, challenges to patent protection for products or product candidates,\ncompetition from other products including biosimilars or disruptive\ntechnologies/business models, changes in laws or regulations, exchange rate\nfluctuations, changes or uncertainties in laws and/or rules pertaining to tax\nand duties or the administration of such laws and/or rules, and hiring,\nretention and compliance of employees. There is no guarantee that new product\ncandidates will be discovered or identified in the pipeline, or that new\nindications for existing products will be developed and approved. Movement\nfrom concept to commercial product is uncertain; preclinical results do not\nguarantee safety and efficacy of product candidates in humans. So far, the\ncomplexity of the human body cannot be reproduced in computer models, cell\nculture systems or animal models. The length of the timing to complete\nclinical trials and to get regulatory approval for product marketing has\nvaried in the past and UCB expects similar unpredictability going forward.\nProducts or potential products which are the subject of partnerships, joint\nventures or licensing collaborations may be subject to disputes between the\npartners or may prove to be not as safe, effective or commercially successful\nas UCB may have believed at the start of such partnership. UCB's efforts\nto acquire other products or companies and to integrate the operations of such\nacquired companies may not be as successful as UCB may have believed at the\nmoment of acquisition. Also, UCB or others could discover safety, side\neffects or manufacturing problems with its products and/or devices after they\nare marketed. The discovery of significant problems with a product similar to\none of UCB's products that implicate an entire class of products may have a\nmaterial adverse effect on sales of the entire class of affected products.\nMoreover, sales may be impacted by international and domestic trends toward\nmanaged care and health care cost containment, including pricing pressure,\npolitical and public scrutiny, customer and prescriber patterns or practices,\nand the reimbursement policies imposed by third-party payers as well as\nlegislation affecting biopharmaceutical pricing and reimbursement activities\nand outcomes. Finally, a breakdown, cyberattack or\ninformation security breach could compromise the confidentiality,\nintegrity and availability of UCB's data and systems.\nGiven these uncertainties, the public is cautioned not to place any undue\nreliance on such forward-looking statements. These forward-looking statements\nare made only as of the date of this document, and do not reflect any\npotential impacts from the evolving event or risk as mentioned above as well\nas any other adversity, unless indicated otherwise. The company continues to\nfollow the development diligently to assess the financial significance of\nthese events, as the case may be, to UCB.\n\nUCB expressly disclaims any obligation to update\nany forward-looking statements in this document, either to confirm the actual results\nor to report or reflect any change in its forward-looking statements with\nregard thereto or any change in events, conditions or circumstances on which\nany such statement is based, unless such statement is required pursuant to\napplicable laws and regulations.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ucb-launches-wear-it-out-a-community-driven-program-created-for-and-with-people-living-with-hidradenitis-suppurativa-plaque-psoriasis-and-psoriatic-arthritis-302906213.html\n(https://www.prnewswire.com/news-releases/ucb-launches-wear-it-out-a-community-driven-program-created-for-and-with-people-living-with-hidradenitis-suppurativa-plaque-psoriasis-and-psoriatic-arthritis-302906213.html)\n\nSOURCE UCB\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS472406/With-Tag-Logo.jpg?id=OA3013834\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5w6VZwa-20261013","title":"UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis","author":"PR Newswire","ticker":"UCB","created":"2026-10-13T13:00:27.621Z","tickers":["UCB"],"exchange":"","article_body":"UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis\nPR Newswire\n\nATLANTA, Oct. 13, 2026\n\n * The Wear It Out program was created with and for patient advocates to reduce\nstigma and increase awareness of the everyday, often unseen compromises and\ndecisions people make because of their conditions.\n * Artist Sophia Yeshi brought real stories of people living with HS, PSO, and\nPsA to life in the form of a t-shirt, transforming them into a wearable\nexpression of connection and self-expression.\n * If you're living with HS, PSO, or PsA, visit\nGoWearItOut.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=3366111021&u=https%3A%2F%2Fwww.gowearitout.com%2F&a=GoWearItOut.com)\n\n to learn how to submit your story, join the community, and receive your\none-of-a-kind Wear It Out t-shirt.\nATLANTA, Oct. 13, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical\ncompany, today announced the launch of Wear It Out\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=2190091215&u=https%3A%2F%2Fwww.gowearitout.com%2F&a=Wear+It+Out)\n, a program created with and for people living with hidradenitis suppurativa\n(HS), plaque psoriasis (PSO), and psoriatic arthritis (PsA). Together, these\nconditions affect millions of people in the U.S., with approximately 2.5\nmillion people living with HS, and approximately 11.3 million people living\nwith PSO or PsA. Developed alongside patient advocates and acclaimed artist\nSophia Yeshi, the Wear It Out program showcases the everyday, often unseen\ndecisions and compromises people make because of their conditions.\n\nWear It Out was born from listening to the community and recognizing a shared\ndesire to feel seen, understood, and empowered. For many people living with\nHS, PSO, and PsA, the impact of disease extends beyond physical symptoms,\nshaping the choices other people often take for granted, like what to wear.\nFor some living with HS, white clothing may feel off limits because drainage\nor leakage from a flare could show. For those living with PSO, black clothing\ncan make flaking more visible, while PsA symptoms, such as stiff or painful\njoints, can make getting dressed, including fastening buttons, more difficult.\n\n\"Getting dressed should not be a strategic decision, and feeling comfortable\nin your own body should never feel out of reach, but for many people with HS,\nPSO, or PsA, it can be–quietly ruling out a white or black shirt or skipping\nan invitation because of what the condition may show,\" said Brittany Blair,\nHead of Patient Strategy, U.S. Immunology, UCB. \"Wear It Out transforms that\nquiet calculation into a visual community symbol worth celebrating and it is a\nreminder that no one should have to settle for less than feeling like\nthemselves in their healthcare journey.\"\n\nAt the center of Wear It Out is a collection of one-of-a-kind,\ncondition-conscious t-shirts, which reclaim those familiar colors as symbols\nof the choices others may never understand. Inspired by the real stories of\npeople living with HS, PSO, and PsA, and brought to life by Brooklyn-based\ngraphic designer and illustrator Sophia Yeshi, each t-shirt design transforms\nlived experiences into a wearable expression of connection and\nself-expression. White and black tees are no longer just everyday wardrobe\nstaples, but reminders that the experiences behind them deserve to be\nrecognized.\n\n\"My work explores themes of identity, resilience, and belonging, so when I was\ngiven the opportunity to create something beautiful out of the often\nchallenging experiences of real people living with these conditions, I was so\ninspired,\" said Sophia Yeshi, graphic designer and illustrator at Yeshi\nDesigns. Every person who shared their story brought a unique perspective and\nsense of strength to this project. My goal was to create artwork that honors\nthose experiences and reflects the beauty, courage, and individuality of the\ncommunity, and thanks to the patients and advocates involved, I think we\nachieved that.\"\n\nThrough shared experiences, community storytelling, and opportunities for\nconnection, the program encourages individuals to celebrate the moments that\nmatter most, whether that means wearing a color they once avoided,\nreconnecting with loved ones, saying yes to new opportunities, or simply\nshowing up with greater confidence.\n\nHS, PSO, and PsA community members can visit GoWearItOut.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=3366111021&u=https%3A%2F%2Fwww.gowearitout.com%2F&a=GoWearItOut.com)\n to join the Wear It Out community, receive resources, and share their own\nstory via video or audio to receive a condition-conscious t-shirt.\n\nFor further information, contact UCB:\n\nInvestor Relations\nYvonne Naughton\nT: +44.175.344.7521\nEmail: Yvonne.Naughton@ucb.com (mailto:Yvonne.Naughton@ucb.com)\n\nSahar Yazdian\nT: +32.2.559.91.37\nEmail: Sahar.Yazdian@ucb.com (mailto:sahar.yazdian@ucb.com)\n\nCorporate Communications\nLaurent Schots\nT: +32.2.559.92.6\nEmail: Laurent.Schots@ucb.com (mailto:Laurent.schots@ucb.com)\n\nU.S. Communications\nNicole Herga\nT +1.773.960.5349\nEmail: Nicole.Herga@ucb.com (mailto:Nicole.Herga@ucb.com)\n\nAbout UCB\nUCB, Brussels, Belgium (www.ucb.com)\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795877-1&h=1188503714&u=http%3A%2F%2Fwww.ucb.com%2F&a=(www.ucb.com))\nis a global biopharmaceutical company focused on the discovery and development\nof innovative medicines and solutions to transform the lives of people living\nwith severe diseases of the immune system or of the central nervous system.\nWith approximately 9,000 people in approximately 40 countries, the company\ngenerated revenue of $ 7.7 billion in 2025. UCB is listed on Euronext Brussels\n(symbol: UCB)\n\nForward-looking statements\nThis document contains forward-looking statements, including, without\nlimitation, statements containing the words \"potential\", \"believes\",\n\"anticipates\", \"expects\", \"intends\", \"plans\", \"seeks\", \"estimates\", \"may\",\n\"will\", \"continue\" and similar expressions. These forward-looking statements\nare based on current plans, estimates and beliefs of management. All\nstatements, other than statements of historical facts, are statements that\ncould be deemed forward-looking statements, including estimates of revenues,\noperating margins, capital expenditures, cash, other financial information,\nexpected legal, arbitration, political, regulatory or clinical results or\npractices and other such estimates and results. By their nature, such\nforward-looking statements are not guaranteeing future performance and are\nsubject to known and unknown risks, uncertainties, and assumptions which might\ncause the actual results, financial condition, performance or achievements\nof UCB, or industry results, to be materially different from any future\nresults, performance, or achievements expressed or implied by such\nforward-looking statements contained in this document.\n\nImportant factors that could result in such differences include but are not\nlimited to: global spread and impacts of wars, pandemics and terrorism, the\ngeneral geopolitical environment, climate change, changes in general economic,\nbusiness and competitive conditions, the inability to obtain necessary\nregulatory approvals or to obtain them on acceptable terms or within expected\ntiming, costs associated with research and development, changes in the\nprospects for products in the pipeline or under development by UCB, effects of\nfuture judicial decisions or governmental investigations, safety, quality,\ndata integrity or manufacturing issues, supply chain disruption and business\ncontinuity risks; potential or actual data security and data privacy breaches,\nor disruptions of UCB's information technology systems, product liability\nclaims, challenges to patent protection for products or product candidates,\ncompetition from other products including biosimilars or disruptive\ntechnologies/business models, changes in laws or regulations, exchange rate\nfluctuations, changes or uncertainties in laws and/or rules pertaining to tax\nand duties or the administration of such laws and/or rules, and hiring,\nretention and compliance of employees. There is no guarantee that new product\ncandidates will be discovered or identified in the pipeline, or that new\nindications for existing products will be developed and approved. Movement\nfrom concept to commercial product is uncertain; preclinical results do not\nguarantee safety and efficacy of product candidates in humans. So far, the\ncomplexity of the human body cannot be reproduced in computer models, cell\nculture systems or animal models. The length of the timing to complete\nclinical trials and to get regulatory approval for product marketing has\nvaried in the past and UCB expects similar unpredictability going forward.\nProducts or potential products which are the subject of partnerships, joint\nventures or licensing collaborations may be subject to disputes between the\npartners or may prove to be not as safe, effective or commercially successful\nas UCB may have believed at the start of such partnership. UCB's efforts\nto acquire other products or companies and to integrate the operations of such\nacquired companies may not be as successful as UCB may have believed at the\nmoment of acquisition. Also, UCB or others could discover safety, side\neffects or manufacturing problems with its products and/or devices after they\nare marketed. The discovery of significant problems with a product similar to\none of UCB's products that implicate an entire class of products may have a\nmaterial adverse effect on sales of the entire class of affected products.\nMoreover, sales may be impacted by international and domestic trends toward\nmanaged care and health care cost containment, including pricing pressure,\npolitical and public scrutiny, customer and prescriber patterns or practices,\nand the reimbursement policies imposed by third-party payers as well as\nlegislation affecting biopharmaceutical pricing and reimbursement activities\nand outcomes. Finally, a breakdown, cyberattack or\ninformation security breach could compromise the confidentiality,\nintegrity and availability of UCB's data and systems.\nGiven these uncertainties, the public is cautioned not to place any undue\nreliance on such forward-looking statements. These forward-looking statements\nare made only as of the date of this document, and do not reflect any\npotential impacts from the evolving event or risk as mentioned above as well\nas any other adversity, unless indicated otherwise. The company continues to\nfollow the development diligently to assess the financial significance of\nthese events, as the case may be, to UCB.\n\nUCB expressly disclaims any obligation to update\nany forward-looking statements in this document, either to confirm the actual results\nor to report or reflect any change in its forward-looking statements with\nregard thereto or any change in events, conditions or circumstances on which\nany such statement is based, unless such statement is required pursuant to\napplicable laws and regulations.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ucb-launches-wear-it-out-a-community-driven-program-created-for-and-with-people-living-with-hidradenitis-suppurativa-plaque-psoriasis-and-psoriatic-arthritis-302906213.html\n(https://www.prnewswire.com/news-releases/ucb-launches-wear-it-out-a-community-driven-program-created-for-and-with-people-living-with-hidradenitis-suppurativa-plaque-psoriasis-and-psoriatic-arthritis-302906213.html)\n\nSOURCE UCB\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS472406/With-Tag-Logo.jpg?id=OA3013834\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T13:00:27.685044931Z","server_sent_at_ms":1791896427685},"received_at":"2026-10-13T13:00:27.735Z","source_url":"https://www.prnewswire.com/news-releases/ucb-launches-wear-it-out-a-community-driven-program-created-for-and-with-people-living-with-hidradenitis-suppurativa-plaque-psoriasis-and-psoriatic-arthritis-302906213.html"},"analysis":{"id":"155997","press_release_id":"167707","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"UCB launched Wear It Out, a community-driven awareness program for people living with hidradenitis suppurativa, plaque psoriasis, and psoriatic arthritis.\n\nThe program, developed with patient advocates and artist Sophia Yeshi, centers on condition-conscious t-shirt designs that acknowledge the everyday clothing compromises patients make.\n\nThe release is a patient-marketing initiative with no new clinical, regulatory, or financial developments for the company; UCB reported 2025 revenue of $7.7 billion in boilerplate.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine patient-community branding campaign -- suppress for trading-relevant alerts."},"keyFigures":{"customDimensions":{"countries":"approximately 40","employees":"approximately 9,000","revenue_2025":"$7.7 billion","hs_patients_us":"approximately 2.5 million","pso_psa_patients_us":"approximately 11.3 million"}},"quotedText":"Getting dressed should not be a strategic decision, and feeling comfortable in your own body should never feel out of reach","namedEntities":{"people":[{"name":"Brittany Blair","role":"Head of Patient Strategy, U.S. Immunology, UCB"},{"name":"Sophia Yeshi","role":"graphic designer and illustrator, Yeshi Designs"},{"name":"Yvonne Naughton","role":"Investor Relations, UCB"},{"name":"Laurent Schots","role":"Corporate Communications, UCB"},{"name":"Nicole Herga","role":"U.S. Communications, UCB"},{"name":"Sahar Yazdian","role":"Investor Relations, UCB"}],"products":["Wear It Out"],"companies":[{"name":"UCB","ticker":"UCB","relationship":"filer"}],"dollarAmounts":[{"amount":"$7.7 billion","context":"UCB 2025 revenue (boilerplate)"}]},"materialImpact":{"score":1,"reasoning":"This is a patient-community awareness/branding campaign ( Wear It Out t-shirt program), not a product, regulatory, or financial event. No revenue, pipeline, or clinical implications disclosed."},"tickerRelevance":{"others":[],"primary":"UCB"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap-international","eventGravity":"awareness-campaign","issuerAuthored":true}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"UCB launched Wear It Out, a community-driven awareness program for people living with hidradenitis suppurativa, plaque psoriasis, and psoriatic arthritis.\n\nThe program, developed with patient advocates and artist Sophia Yeshi, centers on condition-conscious t-shirt designs that acknowledge the everyday clothing compromises patients make.\n\nThe release is a patient-marketing initiative with no new clinical, regulatory, or financial developments for the company; UCB reported 2025 revenue of $7.7 billion in boilerplate.","key_figures":{"customDimensions":{"countries":"approximately 40","employees":"approximately 9,000","revenue_2025":"$7.7 billion","hs_patients_us":"approximately 2.5 million","pso_psa_patients_us":"approximately 11.3 million"}},"named_entities":{"people":[{"name":"Brittany Blair","role":"Head of Patient Strategy, U.S. Immunology, UCB"},{"name":"Sophia Yeshi","role":"graphic designer and illustrator, Yeshi Designs"},{"name":"Yvonne Naughton","role":"Investor Relations, UCB"},{"name":"Laurent Schots","role":"Corporate Communications, UCB"},{"name":"Nicole Herga","role":"U.S. Communications, UCB"},{"name":"Sahar Yazdian","role":"Investor Relations, UCB"}],"products":["Wear It Out"],"companies":[{"name":"UCB","ticker":"UCB","relationship":"filer"}],"dollarAmounts":[{"amount":"$7.7 billion","context":"UCB 2025 revenue (boilerplate)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T13:00:33.289Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"large-cap-international","eventGravity":"awareness-campaign","issuerAuthored":true}},"durationMs":5528,"modelName":"glm-5.3-flashx"}}